NCT00346957已完成2 期
A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 128
- 主要终点
- Mean change in logMAR visual acuity at 12 months from baseline.
研究概览
简要总结
The purpose of the study is to determine the concentration of anecortave acetate (15 or 30 mg versus placebo) that is safe and effective for the inhibition of the growth of blood vessels in the retina in patients with wet AMD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ages 50 years and over
- •Other protocol-defined inclusion and exclusion criteria may apply.
排除标准
- 未提供
研究组 & 干预措施
Anecortave Acetate 30
Experimental
干预措施: Anecortave acetate 30 mg (Drug)
Anecortave Acetate 15
Experimental
干预措施: Anecortave Acetate 15 mg (Drug)
Anecortave Acetate 3
Experimental
干预措施: Anecortave Acetate 3 mg (Drug)
Anecortave Acetate Vehicle
Placebo Comparator
干预措施: Anecortave Acetate Vehicle (Other)
结局指标
主要结局
Mean change in logMAR visual acuity at 12 months from baseline.
时间窗: 12 months
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMDMacular DegenerationNCT00041483Alcon Research530
已完成
3 期
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)Macular DegenerationNCT00299507Alcon Research240
终止
3 期
Anecortave Acetate Risk Reduction Trial (AART)AMDNCT00332657Alcon Research36
已完成
2 期
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) ElevationEye DiseasesNCT00315640Alcon Research70
已完成
3 期
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMDMaculopathy, Age-RelatedMacular DegenerationNCT00058994Alcon Research